With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Worried sarcoma wasn’t one of the multiple primary sites included in the SABR-COMET trial? Here’s a case series of 16 patients with sarcoma treated with SBRT monotherapy for oligomets reporting a remarkable median time to salvage chemo or death of 28 months. | Loi, Radiol Med 2018